CN117503898A - Traditional Chinese medicine composition for treating asthma and application thereof - Google Patents
Traditional Chinese medicine composition for treating asthma and application thereof Download PDFInfo
- Publication number
- CN117503898A CN117503898A CN202311659456.4A CN202311659456A CN117503898A CN 117503898 A CN117503898 A CN 117503898A CN 202311659456 A CN202311659456 A CN 202311659456A CN 117503898 A CN117503898 A CN 117503898A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- treating asthma
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 208000006673 asthma Diseases 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 229940079593 drug Drugs 0.000 claims abstract description 21
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 13
- 241000931705 Cicada Species 0.000 claims abstract description 10
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 10
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 10
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 10
- 235000008397 ginger Nutrition 0.000 claims abstract description 10
- 241000758794 Asarum Species 0.000 claims abstract description 9
- 241000202726 Bupleurum Species 0.000 claims abstract description 9
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 9
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 9
- 241001522129 Pinellia Species 0.000 claims abstract description 9
- 244000018633 Prunus armeniaca Species 0.000 claims abstract description 9
- 235000009827 Prunus armeniaca Nutrition 0.000 claims abstract description 9
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 9
- 241000596154 Belamcanda Species 0.000 claims abstract description 8
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 8
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 8
- 241000218671 Ephedra Species 0.000 claims abstract description 8
- 241000931143 Gleditsia sinensis Species 0.000 claims abstract description 8
- 235000004347 Perilla Nutrition 0.000 claims abstract description 8
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 8
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 8
- 235000011477 liquorice Nutrition 0.000 claims abstract description 8
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 7
- 210000000582 semen Anatomy 0.000 claims abstract description 7
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 4
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 241000207929 Scutellaria Species 0.000 claims description 4
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims description 4
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- -1 glidants Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 2
- 230000002745 absorbent Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 238000001256 steam distillation Methods 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 26
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 17
- 208000026435 phlegm Diseases 0.000 abstract description 17
- 208000024891 symptom Diseases 0.000 abstract description 14
- 241000721047 Danaus plexippus Species 0.000 abstract description 7
- 208000005392 Spasm Diseases 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 12
- 206010011224 Cough Diseases 0.000 description 10
- 206010047924 Wheezing Diseases 0.000 description 10
- 208000037656 Respiratory Sounds Diseases 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 8
- 206010008479 Chest Pain Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 108091033773 MiR-155 Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- 241000801118 Lepidium Species 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960002848 formoterol Drugs 0.000 description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000758795 Aristolochiaceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010051841 Exposure to allergen Diseases 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000596151 Iris domestica Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 101150091206 Nfkbia gene Proteins 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000013128 asthma control test Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000013123 lung function test Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
The invention discloses a traditional Chinese medicine composition for treating asthma and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises the following components in parts by weight: 8-12 parts of cicada slough, 18-22 parts of earthworm, 6-10 parts of ephedra, 6-10 parts of cassia twig, 3-7 parts of dried ginger, 1-5 parts of asarum, 8-12 parts of schisandra chinensis, 8-12 parts of Chinese honeylocust, 8-12 parts of bitter apricot seed, 13-17 parts of semen lepidii, 8-12 parts of perilla fruit, 8-12 parts of bupleurum, 10-14 parts of purified pinellia tuber, 13-17 parts of baikal skullcap root, 13-17 parts of blackberry lily, 8-12 parts of liquorice and 8-12 parts of jujube. The traditional Chinese medicine composition for treating asthma uses worm medicines as monarch medicines, has the advantages of dredging collaterals, dispersing lung qi, resolving phlegm, improving airway spasm of patients, relieving clinical symptoms, being good in compliance, less in adverse reaction, simple and practical, and convenient to popularize and use.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating asthma and application thereof.
Background
Western medicine believes that: asthma is the most common respiratory disease, and people of all ages are ill, and patients suffering from asthma are not spent, whether they are young children, middle aged and elderly people, or young people. This is a chronic airway inflammatory disease, the cause of which is numerous. Some patients are genetically caused, and sometimes ill, due to environmental pollution or cold air irritation of the respiratory mucosa. In addition, exercise can sometimes lead to asthma, some drugs or foods can also lead to asthma, and smoking is also a major factor in the induction of asthma. Other factors such as respiratory viral infections, allergies, are some of the causes of asthma. In recent years, environmental factors have led to an increasing number of asthma.
The aspects of traditional Chinese medicine are as follows: the traditional Chinese medicine has long history of treating asthma, and the causes of asthma are divided into internal and external, the external causes are exogenous pathogenic factors, diet, emotion, fatigue and the like, the internal causes are deficiency of lung, spleen and kidney, and modern doctors provide respective insights according to long-term accumulated clinical practice experience. However, in summary, the internal and external causes do not lead to the deficiency of viscera's healthy qi, the dysfunction of water transportation and transformation, the unsmooth qi movement, the blockage of collaterals and the upward reverse of lung qi become a key pathological factor in the development process of asthma, and the chronic persistent period of asthma is the root cause of the chronic persistent failure of phlegm turbidity to block collaterals.
At present, the domestic and international social researches on glucocorticoid, bronchodilators and the like are effective medicaments for treating asthma, can inhibit proliferation and differentiation of eosinophils, and can effectively reduce the number of inflammatory cells in asthma in circulation. However, it is still insufficient in terms of immunomodulation, and on the one hand, patients with asthma are improved and stopped, causing recurrent attacks of asthma. On the other hand, even though hormones and dilators are inhaled, the patient is still not controlled and the patient repeatedly attacks. Clinical and experimental researches prove that after the patients in the observation group are treated by oral cicada slough decoction and budesonide formoterol powder inhalant, the integral of symptoms such as cough, wheezing, chest distress, expectoration and the like is lower than that in the control group (P < 0.05), the FEV1% and PEF% of the lung function are higher than those in the control group (P < 0.05), and the ACT score is higher than that in the control group (P < 0.05), so that the treatment method of the cicada slough decoction mainly has the effects of dredging collaterals and spasmolysis, regulating qi and ventilating the lung, resolving phlegm and relieving asthma can relieve the respiratory symptoms of asthma patients with haze exposure, improve the lung ventilation function, effectively control the asthma condition, and prove the effectiveness of the cicada slough decoction. Meanwhile, the protection effect of the cicada slough soup on lung injury of asthmatic mice exposed to PM2.5 is observed, and the article is published in J2022.17 (04) of the combination of Western and traditional Chinese medicine in the world.
The main medicine for treating asthma is an inhalation preparation, and due to fear of inhaling hormone, many patients cannot control asthma by persisting in inhaling the medicine, so that asthma is repeatedly attacked, and even if some patients inhale the medicine, the control is not ideal. The existing traditional Chinese medicine preparation can not meet the clinical requirements of patients.
In view of this, the present invention has been proposed.
Disclosure of Invention
Aiming at the problems in the prior art, the existing western medicines cannot meet clinical requirements and have poor patient compliance; the Chinese patent medicine is mainly used for dispersing lung qi and resolving phlegm, and the curative effect is not described when acute exacerbation occurs.
In order to achieve the above purpose, the invention is solved by the following technical scheme:
the traditional Chinese medicine composition for treating asthma comprises the following components in parts by weight: 8-12 parts of cicada slough, 18-22 parts of earthworm, 6-10 parts of ephedra, 6-10 parts of cassia twig, 3-7 parts of dried ginger, 1-5 parts of asarum, 8-12 parts of schisandra chinensis, 8-12 parts of Chinese honeylocust, 8-12 parts of bitter apricot seed, 13-17 parts of semen lepidii, 8-12 parts of perilla fruit, 8-12 parts of bupleurum, 10-14 parts of purified pinellia tuber, 13-17 parts of baikal skullcap root, 13-17 parts of blackberry lily, 8-12 parts of liquorice and 8-12 parts of jujube.
Preferably, the traditional Chinese medicine composition comprises the following components in parts by weight: 10 parts of periostracum cicadae, 20 parts of earthworm, 8 parts of ephedra, 8 parts of cassia twig, 5 parts of dried ginger, 3 parts of asarum, 10 parts of schisandra chinensis, 10 parts of Chinese honeylocust fruit, 10 parts of bitter apricot seed, 15 parts of semen lepidii, 10 parts of perilla fruit, 10 parts of bupleurum, 12 parts of purified pinellia tuber, 15 parts of baical skullcap root, 15 parts of blackberry lily, 10 parts of liquorice and 10 parts of Chinese date.
Preparation method of traditional Chinese medicine composition for treating asthma
Which comprises the following steps: according to the selected weight portions, the cicada slough, earthworm, ephedra herb, cassia twig, dried ginger, asarum, shizandra berry, chinese honeylocust fruit, bitter apricot seed, pepperweed seed, perilla seed, bupleurum, purified pinellia tuber, baikal skullcap root, blackberry lily, liquorice and jujube are weighed, mixed and then extracted according to the conventional extraction method or respectively extracted according to the conventional extraction method and then mixed, thus obtaining the Chinese medicinal composition.
Preferably, the conventional extraction method comprises one or more of soaking extraction, decoction extraction, reflux extraction, percolation extraction, ultrasonic extraction and steam distillation.
More preferably, the method comprises the steps of: the preparation method comprises the steps of putting the raw materials into a traditional Chinese medicine pot, immersing the raw materials in clear water for 20-40 minutes, decocting for 15-20 minutes, pouring the decocted raw materials into a container, continuously adding a proper amount of water into the medicine pot, decocting for 15-20 minutes, and combining the two liquid medicines.
A Chinese medicinal preparation for treating asthma comprises the above Chinese medicinal composition or the Chinese medicinal composition prepared by the above preparation method, and optionally one or more pharmaceutically acceptable carriers.
Preferably, the Chinese medicinal preparation is a tablet, a capsule, a pill, a granule, a solution, a syrup or a decoction.
More preferably, the pharmaceutically acceptable carrier is selected from at least one of pharmaceutically acceptable solvents, solubilizers, co-solvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, integrating agents, permeation promoters, buffers, plasticizers, surfactants, absorbents, diluents, polymeric matrix materials, and film-forming materials.
The application of the traditional Chinese medicine composition or the traditional Chinese medicine preparation in preparing medicines for treating asthma diseases.
The application of the traditional Chinese medicine composition prepared by the preparation method in preparing medicines for treating asthma diseases.
On the basis of ensuring the treatment effect of the original traditional Chinese medicine, the invention provides the preparation method of the powder for the convenience of storage, carrying and taking of patients, and is safe and sanitary and easy to produce and sell.
The traditional Chinese medicine pharmacology of the traditional Chinese medicine preparation for treating asthma is as follows:
cicada slough: the Chinese medicinal composition can be used for removing exogenous evil, dispersing lung qi, dispersing liver qi, soothing liver-qi stagnation, calming endogenous wind and relieving spasm, and treating cough without cough, and has the effects of 'vital qi is stored in the body, and evil is not dry'.
Earthworm: light and thin smell, salty taste, soft phlegm, channels and collaterals searching, qi regulating, toxin expelling, and periostracum Cicadae as monarch drugs, can be used for searching external wind to expel toxin, removing external wind, extinguishing internal wind, and expelling pathogenic factors and stopping wind.
Herba Ephedrae: purging the stagnation of lung qi, freeing lung and relieving asthma, is a monarch drug.
Ramulus Cinnamomi: warm nature, relieving exterior syndrome, dispelling cold, warming meridians, promoting qi circulation, and yang.
Dried ginger: warm middle energizer, dispel cold, warm lung and resolve fluid retention.
Fructus Gleditsiae Abnormalis: resolving phlegm and softening hard masses.
Bitter apricot kernel: the adverse flow of lung qi is reduced, and the combination of the above-mentioned drugs and Ma Huang can restore the effect of dispersing and descending the lung and strengthen the effect of dispersing and dispersing the lung to dispel pathogenic factors.
Asarum herb: pungent and warm, helps yang qi, increases the ability to dispel wind and resolve phlegm.
Herba asari is dry root and rhizome of herba asari of Aristolochiaceae, herba asari of Hancheng or herba asari of Hua, and the former two are known as "Liao herba asari", which is pungent and warm in nature and enters heart, lung and kidney meridians. Herba asari has effects of relieving exterior syndrome, dispelling cold, inducing resuscitation, dispelling pathogenic wind, relieving pain, warming lung, resolving food stagnation, relieving fever, relieving pain, anesthesia, relieving convulsion, inhibiting bacteria, and expelling parasite, and is a common Chinese medicinal preparation in clinical practice, but has certain toxic side effects, and herba asari poisoning is caused by directly swallowing single powder or decocting in decoction for too short time, and clinical administration can be controlled by compatibility, processing, standardizing dosage, selecting proper dosage, etc., so as to achieve safe and effective administration. The study is carried out under the conditions of strictly controlling the dosage, selecting a proper processing mode and ensuring the medication safety and being harmless to human bodies.
Purified pinellia tuber: warm and resolve cold phlegm, dry dampness and resolve phlegm.
Radix Scutellariae Baicalensis: lung heat is released, dampness is removed and phlegm is removed.
Chinese magnoliavine fruit: warm nature, sweet and sour taste, astringing lung and nourishing yin, astringing lung qi and receiving kidney qi, and can alleviate the contracture of airway.
Fructus Perillae: descending the adverse flow of lung qi and resolving phlegm and saliva.
Pepperweed seed: for cough and dyspnea due to lung discharge, it is indicated for phlegm-fluid retention in lung.
Blackberry lily: enters the lung meridian to clear and resolve phlegm-fire and phlegm-heat in the lung.
Bupleurum root: the medicine can promote the circulation of the medicine, help the monarch medicine and the diaphoresis machine, and disperse the toxin.
Jujube and licorice: reconciling the medicines.
According to the invention, the worm is mainly used as a monarch drug, namely the periostracum cicadae and the earthworm are used as monarch drugs, the meridian obstruction and the spasm of the airway are considered to be the pathogenesis of asthma with pathogenic factors outside and phlegm retention inside, and the airway is blocked, so that the airway spasm is caused. Large-scale treatment of asthma: spasmolysis, dredging collaterals, warming and resolving phlegm, descending qi and relieving asthma.
Compared with the prior art, the invention has the following beneficial effects:
the traditional Chinese medicine composition for treating asthma provided by the invention takes worm medicines as monarch medicines, and has the advantages of dredging collaterals, ventilating lung, resolving phlegm, improving airway spasm of patients, relieving clinical symptoms, along with good compliance, less adverse reaction, simplicity, practicality and convenience in popularization and application.
Detailed Description
Example 1
The embodiment provides a traditional Chinese medicine composition for treating asthma, which comprises the following components: 10 parts of periostracum cicadae, 20 parts of earthworm, 8 parts of ephedra, 8 parts of cassia twig, 5 parts of dried ginger, 3 parts of asarum, 10 parts of schisandra chinensis, 10 parts of Chinese honeylocust fruit, 10 parts of bitter apricot seed, 15 parts of semen lepidii, 10 parts of perilla fruit, 10 parts of bupleurum, 12 parts of purified pinellia tuber, 15 parts of baical skullcap root, 15 parts of blackberry lily, 10 parts of liquorice and 10 parts of Chinese date.
The preparation method of the traditional Chinese medicine composition comprises the following steps: the medicines are put into a traditional Chinese medicine pot, immersed in clear water for 30 minutes, decocted for 15-20 minutes, the decocted medicines are poured into a container for about 150ml, the immersed traditional Chinese medicine is continuously added into the medicine pot for 10 minutes, the medicines are continuously poured into a container for charging, and the two medicines are mixed for about 300ml.
Example 2
1. Selecting a patient: the Western diagnosis of the subjects in this study was referred to the "guidelines for the prevention and treatment of bronchial asthma (revision 2016)" established by the respiratory disease institute of the Chinese medical society. Diagnostic criteria were as follows:
(1) Recurrent episodes of wheezing, shortness of breath, chest distress or cough are often associated with exposure to allergens, cold air, physical and chemical stimuli, viral upper respiratory infections, exercise, etc.
(2) The lung can be smelled and dispersed or diffuse during the attack, wheeze with the expiratory phase as the main part and the expiratory phase as the extension.
(3) The symptoms can be relieved by treatment or by self.
(4) Except for wheezing, shortness of breath, chest distress and cough caused by other diseases. (5) The atypical clinical manifestations (e.g. no significant wheezing or signs) should be provided with at least one of the following
Positive test:
(1) bronchial excitation test or exercise test positive:
(2) broncho-diastole test positive [ one second forced expiratory volume (FEV 1) increase by more than 15%, and FEV1 increase absolute > 200ml ]:
(3) the daily variation rate or the diurnal fluctuation rate of the maximum expiratory flow (PEF) is more than or equal to 20 percent.
Meets 1-4 or 5 patients, and can be used for diagnosing bronchial asthma.
61 cases of asthmatic patients are selected according to the diagnosis standard of the "bronchial asthma control guidelines (2016 revision)" formulated by the respiratory disease institute of the China medical society, and are divided into 31 cases of observation groups, 30 cases of control groups by adopting a random number table method: according to the treatment method in the global asthma control initiative (GINA), budesonide formoterol powder inhalant (specification: 160 μg/4.5 μg/inhalation, manufactured by aslican pharmaceutical limited company, sweden, national medicine standard H20090773), 1 inhalation/time, 2 times/day, was regularly used.
Observation group: the traditional Chinese medicine composition prepared in the example 1 is combined on the basis of conventional treatment of a control group. The medicines are taken from a traditional Chinese medicine pharmacy in the middle hospital of Hebei province, all indexes meet pharmacopoeia requirements, and are uniformly decocted by an automatic decoction machine in a decoction room of the middle hospital of Hebei province, 400ml of juice is taken, 1 dose is taken after 2 meals a day.
2. Standard of efficacy:
(1) Symptom score: compared with the prior treatment, the symptoms of cough, wheezing, chest distress and expectoration of the two groups of patients after treatment are reduced, the difference is statistically significant (P < 0.05), and the symptoms of the group observed after treatment are lower than those of the control group, and the difference is statistically significant (P < 0.05).
(2) Pulmonary function results: the two groups of patients had elevated FEV1%, PEF% compared to pre-treatment, the differences were statistically significant (P < 0.05), and the post-treatment observed group was higher than the control group, the differences were statistically significant (P < 0.05).
(3) ACT scoring results: the ACT scores were both increased in both post-treatment patients compared to pre-treatment, with statistically significant differences (P < 0.05), and the post-treatment observations were higher than the controls, with statistically significant differences (P < 0.05).
(4) Laboratory test results: compared with the serum of two groups of patients before treatment, the serum of the two groups of patients after treatment has reduced IgE, IL-17 and TNF-alpha levels and NF-kBP and IkB alpha levels, the relative expression level of miR-155 is reduced, the difference has statistical significance (P < 0.05), the IL-10 level of the observation group is increased, the difference has statistical significance (P < 0.05), and the difference between the treated index observation group and the control group is obvious, and the difference has statistical significance (P < 0.05).
3. Treatment course: four weeks are a course of treatment.
4. The treatment effect is as follows:
(1) The intervention of the traditional Chinese medicine composition prepared in the embodiment 1 can improve the symptoms of cough, wheezing, chest distress, expectoration and other traditional Chinese medicine symptoms of asthma patients, and can improve the lung function and asthma control test scores.
(2) The intervention of the traditional Chinese medicine composition prepared in the example 1 can reduce the total IgE in serum of asthmatic patients, reduce the levels of TNF-a and IL-17, raise the level of IL-10, reduce the levels of NF-KB and IkBa and reduce the expression level of miR-155. The action mechanism of the polypeptide can be related to down-regulating miR-155 expression, inhibiting NF-kB pathway over-activation and regulating inflammatory factor level.
5. Comparison of the efficacy of the observations versus the controls:
Note:*Compared with the same group before treatment(P<0.05)；#Comparedwith the control group(P<0.05)
Note:*Compared with the same group before treatment(P<0.05)；#Comparedwith the control group(P<0.05)
Note:*Compared with the same group before treatment(P<0.05)；#Comparedwith the control group(P<0.05)
Note:*Compared with the same group before treatment(P<0.05)；#Comparedwith the control group(P<0.05)
Note:*Compared with the same group before treatment(P<0.05)；#Comparedwith the control group(P<0.05)
the traditional Chinese medicine composition used in the observation group in the study is a formula according to the mechanism of asthma caused by haze in the local area, has been applied in clinic for years, and can effectively relieve cough, expectoration, dyspnea, wheezing and other symptoms of asthmatic patients and reduce the times of asthma attack and reexamination. Before the clinical trial study, animal experiments were carried out to verify the effectiveness and safety of the traditional Chinese medicine composition, and the animal experiments show that compared with the asthma mice caused by OVA under clean air, the asthma mice caused by OVA after PM2.5 contamination can aggravate the manifestations of sneeze, nodulation respiration, wheezing and the like, and pathological results show that the manifestations of inflammatory cell infiltration, interstitial thickening, irregular alveolar space and the like of the lung tissue of the mice, and the asthma symptoms and lung injury of the mice can be obviously improved after the traditional Chinese medicine composition prepared in the embodiment 1 is used for lavaging. The poria cocos, radix schisandrae chinensis and ginger decoction contained in the traditional Chinese medicine composition can be used for treating bronchial asthma, can reduce the levels of organism TNF-a, IL-4 and IL-17, inhibit airway inflammation, improve airway obstruction, increase the content of immune protein and improve immunity under cold conditions, and the prescription also comprises three stropanting decoction, and is proved to have obvious curative effects on cough and asthma caused by haze, and can reduce airway inflammation and improve airway reconstruction.
Test example 1
Li Mou Man, 54 years old, staff. Asthma is repeatedly developed for 3 years, aggravated in winter, and is treated in a plurality of hospitals once, and the asthma is used for hormone, bronchodilators and traditional Chinese medicine decoction, has no obvious effect and is treated in the outpatient service of the hospital. The medicine liquid prepared in the example 1 (1 dose is one day of medicine), and after one week of continuous administration, the treatment is carried out by reducing wheezing and chest distress by more than 40% compared with the treatment before, and the treatment is carried out for two weeks, and the times of asthma attack are obviously reduced compared with the treatment before.
Test example 2
Zhu Mou women, 25 years old, workers. The asthma of the patient is treated by combining Chinese and Western medicines in a plurality of hospitals for 1 year, the patients are not improved, and the symptoms of the asthma are gradually aggravated every time the patients meet the stimulus gas, and then the patients visit the hospital. The Chinese medicinal composition of example 1 (1 dose is one day of dosage) is used for treating asthma of I' me family (cupping, acupoint application and acupoint injection). After one week of administration, the onset is reduced by about 50% before, and then the treatment is continued for two weeks as before, so that the symptoms are obviously reduced, the pain during asthma attack is greatly reduced, and the treatment is carried out after one week.
The above embodiments are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solutions of the present invention should fall within the protection scope defined by the claims of the present invention without departing from the design spirit of the present invention.
Claims (10)
1. The traditional Chinese medicine composition for treating asthma is characterized by comprising the following components in parts by weight: 8-12 parts of cicada slough, 18-22 parts of earthworm, 6-10 parts of ephedra, 6-10 parts of cassia twig, 3-7 parts of dried ginger, 1-5 parts of asarum, 8-12 parts of schisandra chinensis, 8-12 parts of Chinese honeylocust, 8-12 parts of bitter apricot seed, 13-17 parts of semen lepidii, 8-12 parts of perilla fruit, 8-12 parts of bupleurum, 10-14 parts of purified pinellia tuber, 13-17 parts of baikal skullcap root, 13-17 parts of blackberry lily, 8-12 parts of liquorice and 8-12 parts of jujube.
2. The traditional Chinese medicine composition for treating asthma according to claim 1, wherein the traditional Chinese medicine composition comprises the following components in parts by weight: 10 parts of periostracum cicadae, 20 parts of earthworm, 8 parts of ephedra, 8 parts of cassia twig, 5 parts of dried ginger, 3 parts of asarum, 10 parts of schisandra chinensis, 10 parts of Chinese honeylocust fruit, 10 parts of bitter apricot seed, 15 parts of semen lepidii, 10 parts of perilla fruit, 10 parts of bupleurum, 12 parts of purified pinellia tuber, 15 parts of baical skullcap root, 15 parts of blackberry lily, 10 parts of liquorice and 10 parts of Chinese date.
3. A method for preparing a traditional Chinese medicine composition for treating asthma according to claim 1 or claim 2, which is characterized in that periostracum cicada, earthworm, ephedra, cassia twig, dried ginger, asarum, schisandra chinensis, chinese honeylocust fruit, bitter apricot seed, semen lepidii, perilla fruit, bupleurum, purified pinellia tuber, baical skullcap root, blackberry lily, liquorice and Chinese date are weighed according to selected parts by weight, are extracted according to a conventional extraction method after being mixed or are respectively extracted according to a conventional extraction method and are mixed, and the traditional Chinese medicine composition is obtained.
4. The method for preparing a Chinese medicinal composition for treating asthma according to claim 3, wherein the conventional extraction method comprises one or more of soaking extraction, decoction extraction, reflux extraction, percolation extraction, ultrasonic extraction and steam distillation.
5. The method for preparing a traditional Chinese medicine composition for treating asthma according to claim 3 or claim 4, comprising the following steps: the preparation method comprises the steps of putting the raw materials into a traditional Chinese medicine pot, immersing the raw materials in clear water for 20-40 minutes, decocting for 15-20 minutes, pouring the decocted raw materials into a container, continuously adding a proper amount of water into the medicine pot, decocting for 15-20 minutes, and combining the two liquid medicines.
6. A Chinese medicinal preparation for treating asthma, comprising the Chinese medicinal composition according to claim 1 or claim 2 or the Chinese medicinal composition prepared by the preparation method according to any one of claims 3 to 5, and optionally one or more pharmaceutically acceptable carriers.
7. The Chinese medicinal preparation for treating asthma according to claim 6, wherein the Chinese medicinal preparation is a tablet, capsule, pill, granule, solution, syrup or extract.
8. The traditional Chinese medicine preparation for treating asthma according to claim 7, wherein the pharmaceutically acceptable carrier is at least one selected from pharmaceutically acceptable solvents, solubilizers, co-solvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, integrating agents, permeation promoters, buffers, plasticizers, surfactants, absorbents, diluents, polymeric matrix materials and film-forming materials.
9. Use of a Chinese medicinal composition according to claim 1 or claim 2 or a Chinese medicinal formulation according to claim 7 or claim 8 in the manufacture of a medicament for the treatment of asthma.
10. The use of the Chinese medicinal composition prepared by the preparation method of claim 3 in the preparation of a medicament for treating asthma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311659456.4A CN117503898A (en) | 2023-12-06 | 2023-12-06 | Traditional Chinese medicine composition for treating asthma and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311659456.4A CN117503898A (en) | 2023-12-06 | 2023-12-06 | Traditional Chinese medicine composition for treating asthma and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117503898A true CN117503898A (en) | 2024-02-06 |
Family
ID=89745596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311659456.4A Pending CN117503898A (en) | 2023-12-06 | 2023-12-06 | Traditional Chinese medicine composition for treating asthma and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117503898A (en) |
-
2023
- 2023-12-06 CN CN202311659456.4A patent/CN117503898A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014139255A1 (en) | Pharmaceutical composition for treating cancers and preparation method thereof | |
| KR20120038989A (en) | Pharmaceutical composition containing ephedrae herba for treating bronchitis and preparation method thereof | |
| CN106138360A (en) | A kind of Chinese medicine composition and preparation method thereof, application | |
| CN111773308A (en) | Traditional Chinese medicine composition of 'lung-ventilating and toxin-expelling decoction' for preventing and treating new coronary pneumonia and preparation method | |
| CN109954034A (en) | A kind of preparation method for treating chill, wind-heat, the drug of influenza and its oral solution | |
| CN111467459B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia at recovery stage, application and preparation method thereof | |
| CN116139237B (en) | A Chinese medicinal composition for preventing and treating respiratory tract infection caused by coronavirus, and its application | |
| CN105497723A (en) | Traditional Chinese medicine preparation for treating bacterial pneumonia and preparation method thereof | |
| CN117503898A (en) | Traditional Chinese medicine composition for treating asthma and application thereof | |
| CN102908607B (en) | External traditional Chinese medicine for treating chronic simple rhinitis and preparation method thereof | |
| CN101138602A (en) | Kidney-nourishing gout-treating capsule | |
| CN103893488A (en) | Chinese medicine preparation for treating migraine and preparation method thereof | |
| CN104367975A (en) | Flos farfarae paste for relieving cough and eliminating phlegm | |
| CN104353045A (en) | Walnut cream with asthma preventing effect | |
| CN102784344B (en) | Traditional Chinese medicine preparation for treating pulmonary tuberculosis | |
| CN114470110B (en) | Anti-rhinitis traditional Chinese medicine composition with pain relieving effect | |
| JP6708916B1 (en) | Zhuang family pharmaceutical composition for regulating replenishment and method for preparing the same | |
| CN106983721A (en) | Treat spray of asthma and preparation method thereof | |
| Wang et al. | Research Progress on Recognition and Treatment of RSV Infection in Traditional Chinese Medicine | |
| CN105343167A (en) | Nasal drop for easing joint movement and opening orifices | |
| CN112641899A (en) | Medicine for quickly eliminating halitosis | |
| CN104491703A (en) | Oral traditional Chinese medicine composition for treating traumatic synovitis of knee joint | |
| CN105194545B (en) | A kind of Chinese medicine composition for treating asthma | |
| CN103751494A (en) | Traditional Chinese medicine composition for treating pertussis | |
| CN104547768A (en) | Health tea used for chronic cough |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |